Biologic characteristics of premalignant breast disease

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 177-192

  Cole, Kimberly ^a   Tabernero, Maria ^b   Anderson, Karen S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

benign breast disease; biomarkers; Breast cancer

Indexed keywords

ALPHA CATENIN; APC PROTEIN; APOLIPOPROTEIN D; BETA CATENIN; BIOLOGICAL MARKER; CYCLIN B1; CYCLIN D2; CYCLOPHILIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE B; LIVIN; MASPIN; MYC PROTEIN; PLAKOGLOBIN; PROGESTERONE RECEPTOR; PROTEIN P53; PSORIASIN; RNA; SURVIVIN; TRASTUZUMAB; UVOMORULIN;

ANTIBODY RESPONSE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DISEASE; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DOWN REGULATION; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MAMMOGRAPHY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955211478     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0187     Document Type: Article

References (199)

1. Screening for breast cancer: U. S. Preventive Services Task Force recommendation statement, Ann Intern Med 151 (2009), 716-726, W-236.
2. K. Aigner et al. , The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity, Oncogene 26 (2007), 6979-6988.
3. M. Al-Hajj et al. , Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A 100 (2003), 3983-3988.
4. K. S. Albain et al. , Prognostic and predictive value of the 21- gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol 11, 55-65.
5. M. R. Alison et al. , Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol 222, 335-344.
6. D. C. Allred et al. , Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer, Hum Pathol 23 (1992), 974-979.
7. D. C. Allred et al. , Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution, Clin Cancer Res 14 (2008), 370-378.
8. C. E. Alpers and S. R. Wellings, The prevalence of carcinoma in situ in normal and cancer-associated breasts, Hum Pathol 16 (1985), 796-807.
9. M. Amari et al. , LOHanalyses of premalignant andmalignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia, Oncol Rep 6 (1999), 1277-1280.
10. B. O. Anderson et al. , Evolving concepts in the management of lobular neoplasia, J Natl Compr Canc Netw 4 (2006), 511-522.
11. K. S. Anderson et al. , Detection of psoriasin/S100A7 in the sera of patients with psoriasis, Br J Dermatol 160 (2009), 325-332.
12. K. S. Anderson et al. , Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer, J Proteome Res 7 (2008), 1490-1499.
13. C. L. Arteaga, Inhibition of TGFbeta signaling in cancer therapy, Curr Opin Genet Dev 16 (2006), 30-37.
14. M. Aubele et al. , Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH, Int J Cancer 85 (2000), 82-86.
15. G. A. Balogh et al. , Mutant p53 protein in serum could be used as a molecular marker in human breast cancer, Int J Oncol 28 (2006), 995-1002.
16. V. J. Bardou et al. , Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol 21 (2003), 1973-1979.
17. R. Barnes and S. Masood, Potential value of hormone receptor assay in carcinoma in situ of breast, Am J Clin Pathol 94 (1990), 533-537.
18. A. Barski et al. , High-resolution profiling of histone methylations in the human genome, Cell 129 (2007), 823-837.
19. B. Baum et al. , Transitions between epithelial and mesenchymal states in development and disease, Semin Cell Dev Biol 19 (2008), 294-308.
20. S. W. Beenken et al. , Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53, Ann Surg 233 (2001), 630-638.
21. D. A. Berry et al. , Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med 353 (2005), 1784-1792.
22. G. Berx et al. , E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain, Oncogene 13 (1996), 1919-1925.
23. K. J. Briegel, Embryonic transcription factors in human breast cancer, IUBMB Life 58 (2006), 123-132.
24. H. Buerger et al. , Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution, J Pathol 194 (2001), 165-170.
25. H. Buerger et al. , Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways, J Pathol 187 (1999), 396-402.
26. G. A. Calin and C. M. Croce, MicroRNA signatures in human cancers, Nat Rev Cancer 6 (2006), 857-866.
27. D. Cao et al. , Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9, Breast Cancer Res 10 (2008), R91.
28. L. A. Carey et al. , Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Jama 295 (2006), 2492-2502.
29. H. Y. Chang et al. , Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival, Proc Natl Acad Sci U S A 102 (2005), 3738-3743.
30. J. C. Chang et al. , Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, Lancet 362 (2003), 362-369.
31. C. Chapman et al. , Autoantibodies in breast cancer: their use as an aid to early diagnosis, Ann Oncol 18 (2007), 868-873.
32. E. Charafe-Jauffret et al. , Aldehyde dehydrogenase 1- positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer, Clin Cancer Res 16, 45-55.
33. Y. Y. Chen et al. , Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast, Am J Surg Pathol 33 (2009), 1683-1694.
34. A. S. Cheng et al. , Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-likemethylome, Cancer Res 68 (2008), 1786-1796.
35. G. Z. Cheng et al. , Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increasedmigration, invasion, and resistance to paclitaxel, Cancer Res 67 (2007), 1979-1987.
36. K. Chin et al. , Genomic and transcriptional aberrations linked to breast cancer pathophysiologies, Cancer Cell 10 (2006), 529-541.
37. M. Chitemerere et al. , TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast, Breast Cancer Res Treat 41 (1996), 103-109.
38. M. F. Clarke and M. Fuller, Stem cells and cancer: two faces of eve, Cell 124 (2006), 1111-1115.
39. L. C. Collins et al. , Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study, Cancer 109 (2007), 180-187.
40. R. Colomer et al. , It is not time to stop progesterone receptor testing in breast cancer, J Clin Oncol 23 (2005), 3868-3869; author reply 3869-3870.
41. L. Da Silva et al. , Aberrant expression of E-cadherin in lobular carcinomas of the breast, Am J Surg Pathol 32 (2008), 773-783.
42. H. Dai et al. , A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients, Cancer Res 65 (2005), 4059-4066.
43. J. Debnath et al. , The role of apoptosis in creating and maintaining luminal space within normal and oncogeneexpressing mammary acini, Cell 111 (2002), 29-40.
44. C. Desmetz et al. , Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women, Clin Cancer Res 15 (2009), 4733-4741.
45. S. Di Saverio et al. , 259 patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up, Breast Cancer Res Treat 109 (2008), 405-416.
46. M. L. Disis et al. , High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer, J Clin Oncol 15 (1997), 3363-3367.
47. W. Domagala et al. , Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive, Virchows Arch A Pathol Anat Histopathol 423 (1993), 497-502.
48. G. Dontu and E. de Rinaldis, MicroRNAs: shortcuts in dealing with molecular complexity? Breast Cancer Res 12, 301
49. G. Dontu et al. , In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells, Genes Dev 17 (2003), 1253-1270.
50. S. Droufakou et al. , Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast, Int J Cancer 92 (2001), 404-408.
51. W. D. Dupont and D. L. Page, Risk factors for breast cancer in women with proliferative breast disease, N Engl J Med 312 (1985), 146-151.
52. R. M. Elledge et al. , Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int J Cancer 89 (2000), 111-117.
53. L. Esserman et al. , Rethinking screening for breast cancer and prostate cancer, Jama 302 (2009), 1685-1692.
54. L. J. Esserman et al. , A role for biomarkers in the screening and diagnosis of breast cancer in younger women, Expert Rev Mol Diagn 7 (2007), 533-544.
55. M. Esteller, Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes, Eur J Cancer 36 (2000), 2294-2300.
56. M. J. Fackler et al. , DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma, Int J Cancer 107 (2003), 970-975.
57. M. J. Fackler et al. , Quantitative multiplex methylationspecific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer, Cancer Res 64 (2004), 4442-4452.
58. M. Fan et al. , Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant, CancerRes 66 (2006), 11954-11966.
59. G. Farnie and R. B. Clarke, Mammary stem cells and breast cancer - role of Notch signalling, Stem Cell Rev 3 (2007), 169-175.
60. F. Fernandez-Madrid et al. , Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer, Cancer Res 64 (2004), 5089-5096.
61. F. W. Foote and F. W. Stewart, Lobular carcinoma in situ: A rare form of mammary cancer, Am J Pathol 17 (1941), 491- 496, 493.
62. E. R. Frykberg, Lobular Carcinoma In Situ of the Breast, Breast J 5 (1999), 296-303.
63. F. Gao et al. , Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies, Am J Clin Pathol 133, 767-771.
64. R. J. Gao et al. , The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters, Breast Cancer Res Treat 93 (2005), 111-115.
65. P. A. Gregory et al. , The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, Nat Cell Biol 10 (2008), 593-601.
66. S. L. Grimm and J. M. Rosen, The role of C/EBPbeta in mammary gland development and breast cancer, JMammary Gland Biol Neoplasia 8 (2003), 191-204.
67. A. Gupta et al. , Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma, Cancer Res 63 (2003), 664-673.
68. S. M. Hammond, MicroRNAs as tumor suppressors, Nat Genet 39 (2007), 582-583.
69. J. Hannemann et al. , Classification of ductal carcinoma in situ by gene expression profiling, Breast Cancer Res 8 (2006), R61.
70. J. R. Harris, M. E. Lippman, M. Morrow and C. K. Osborne, Diseases of the Breast (ed 4th) 69-85 (2010), 321-340.
71. L. C. Hartmann et al. , Benign breast disease and the risk of breast cancer, N Engl J Med 353 (2005), 229-237.
72. E. D. Hay, The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it, Dev Dyn 233 (2005), 706-720.
73. H. M. Heneghan et al. , MicroRNAs as Novel Biomarkers for Breast Cancer, J Oncol 2009 (2009), 950201.
74. M. Hu et al. , Methylation-specific digital karyotyping, Nat Protoc 1 (2006), 1621-1636.
75. M. Huetal. , Regulationof insitu to invasivebreast carcinoma transition, Cancer Cell 13 (2008), 394-406.
76. H. Hugo et al. , Epithelial-mesenchymal and mesenchymal- epithelial transitions in carcinoma progression, JCell Physiol 213 (2007), 374-383.
77. E. S. Hwang et al. , Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma, Cancer 100 (2004), 2562-2572.
78. E. S. Hwang et al. , Patterns of chromosomal alterations in breast ductal carcinoma in situ, Clin Cancer Res 10 (2004), 5160-5167.
79. M. Inui et al. , MicroRNA control of signal transduction, Nat Rev Mol Cell Biol 11 252-263.
80. D. James et al. , TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells, Development 132 (2005), 1273-1282.
81. A. Jemal et al. , Cancer statistics, 2009, CA Cancer J Clin 59 (2009), 225-249.
82. D. Kanojia et al. , Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer, Cancer Epidemiol Biomarkers Prev 18 (2009), 630-639.
83. J. A. Koziol et al. , Recursive partitioning as an approach to selection of immune markers for tumor diagnosis, Clin Cancer Res 9 (2003), 5120-5126.
84. C. Kudo-Saito et al. , Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells, Cancer Cell 15 (2009), 195-206.
85. N. Kwaepila et al. , Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis? Pathology 38 (2006), 125-131.
86. S. R. Lakhani et al. , Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p, J Clin Pathol 48 (1995), 611-615.
87. D. E. Lamendola et al. , Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line, Cancer Res 63 (2003), 2200-2205.
88. P. S. Larson et al. , Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors, J Pathol 209 (2006), 307-316.
89. R. C. Lee et al. , The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin- 14, Cell 75 (1993), 843-854.
90. S. Lee et al. , Alterations of gene expression in the development of early hyperplastic precursors of breast cancer, Am J Pathol 171 (2007), 252-262.
91. C. D. Lehman and R. A. Smith, The role of MRI in breast cancer screening, J Natl Compr Canc Netw 7 (2009), 1109-1115.
92. U. Lehmann et al. , Epigenetic inactivation ofmicroRNAgene hsa-mir-9-1 in human breast cancer, J Pathol 214 (2008), 17-24.
93. P. Lenner et al. , Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a populationbased epidemiological study, Br J Cancer 79 (1999), 927-932.
94. M. F. Lerwill, The evolution of lobular neoplasia, Adv Anat Pathol 13 (2006), 157-165.
95. H. Li et al. , PIK3CA mutations mostly begin to develop inductal carcinoma of the breast, Exp Mol athol 88, 150-155.
96. R. Liu et al. , The prognostic role of a gene signature from tumorigenic breast-cancer cells, N Engl J Med 356 (2007), 217-226.
97. P. K. Lo and S. Sukumar, Epigenomics and breast cancer, Pharmacogenomics 9 (2008), 1879-1902.
98. S. J. London et al. , A prospective study of benign breast disease and the risk of breast cancer, JAMA 67 (1992), 941-944.
99. M. A. Lopez-Garcia et al. , Breast cancer precursors revisited: molecular features and progression pathways, Histopathology 57 171-192.
100. A. J. Lowery et al. , MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer, Breast Cancer Res 11 (2009), R27.
101. Y. J. Lu et al. , Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia, Cancer Res 58 (1998), 4721-4727.
102. A. Lujambio et al. , AmicroRNA DNAmethylation signature for human cancer metastasis, Proc Natl Acad Sci U S A 105 (2008), 13556-13561.
103. M. D. Lynch et al. , Breast cancer, stem cells and prospects for therapy, Breast Cancer Res 8 (2006), 211.
104. L. Ma et al. , Tumour invasion and metastasis initiated by microRNA-10b in breast cancer, Nature 449 (2007), 682-688.
105. X. J. Ma et al. , The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer, J Clin Oncol 24 (2006), 4611-4619.
106. X. J. Ma et al. , Gene expression profiles of human breast cancer progression, Proc Natl Acad Sci U S A 100 (2003), 5974-5979.
107. S. A. Mani et al. , Mesenchyme Forkhead 1 (FOXC2) plays a key role inmetastasis and is associated with aggressive basallike breast cancers, Proc Natl Acad Sci U S A 104 (2007), 10069-10074.
108. S. A. Mani et al. , The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell 133 (2008), 704-715.
109. L. M. Marshall et al. , Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types, Cancer Epidemiol Biomarkers Prev 6 (1997), 297-301.
110. T. L. Mastracci et al. , E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast, Mod Pathol 18 (2005), 741-751.
111. T. L. Mastracci et al. , Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast, Genes Chromosomes Cancer 45 (2006), 1007-1017.
112. R. W. McDivitt et al. , Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group, Cancer 69 (1992), 1408-1414.
113. B. K. McLaren et al. , Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy, Cancer 107 (2006), 1227-1233.
114. R. Mechera et al. , Factors predicting in-breast tumor recurrence after breast-conserving surgery, Breast Cancer Res Treat 116 (2009), 171-177.
115. L. P. Middleton et al. , Expression of ERalpha and ERbeta in lobular carcinoma in situ, Histopathology 50 (2007), 875-880.
116. T. S. Mikkelsen et al. , Genome-wide maps of chromatin state in pluripotent and lineage-committed cells, Nature 448 (2007), 553-560.
117. E. A. Miska, MicroRNAs-keeping cells in formation, Nat Cell Biol 10 (2008), 501-502.
118. S. K. Mohsin et al. , Biomarker profile and genetic abnormalities in lobular carcinoma in situ, Breast Cancer Res Treat 90 (2005), 249-256.
119. A. P. Morel et al. , Generation of breast cancer stem cells through epithelial-mesenchymal transition, PLoS ONE 3 (2008), e2888.
120. Moshin. Modern Pathology, 2005.
121. C. S. Nagi et al. , Lobular neoplasia on core needle biopsy does not require excision, Cancer 112 (2008), 2152-2158.
122. R. Nayar et al. , Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction, Hum Pathol 28 (1997), 277-282.
123. A. Nonni et al. , Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia, Virchows Arch 451 (2007), 893-897.
124. P. O'Connell et al. , Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci, J Natl Cancer Inst 90 (1998), 697-703.
125. D. S. Oh et al. , Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers, J Clin Oncol 24 (2006), 1656-1664.
126. G. L. Ottesen et al. , Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy, Breast Cancer Res Treat 60 (2000), 219-226.
127. D. L. Page et al. , Atypical hyperplastic lesions of the female breast. A long-term follow-up study, Cancer 55 (1985), 2698-2708.
128. D. L. Page et al. , Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease, Hum Pathol 22 (1991), 1232-1239.
129. D. L. Page et al. , Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study, Lancet 361 (2003), 125-129.
130. S. Paik et al. , Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol 24 (2006), 3726-3734.
131. S. Paik et al. , A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, NEngl JMed 351 (2004), 2817-2826.
132. P. Pakneshan et al. , Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis, J Biol Chem 279 (2004), 31735-31744.
133. D. M. Parkin et al. , Global cancer statistics, 2002, CA Cancer J Clin 55 (2005), 74-108.
134. L. Patrawala et al. , Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic, Cancer Res 65 (2005), 6207-6219.
135. M. S. Pepe et al. , Phases of biomarker development for early detection of cancer, JNatlCancer Inst 93 (2001), 1054-1061.
136. C. M. Perou et al. , Molecular portraits of human breast tumours, Nature 406 (2000), 747-752.
137. K. Polyak and W. C. Hahn, Roots and stems: stem cells in cancer, Nat Med 12 (2006), 296-300.
138. K. Polyak and R. A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat Rev Cancer 9 (2009), 265-273.
139. D. Ponti et al. , Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties, Cancer Res 65 (2005), 5506-5511.
140. S. E. Pories et al. , Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment, Cancer Epidemiol Biomarkers Prev 17 (2008), 1034-1042.
141. D. Porter et al. , Molecular markers in ductal carcinoma in situ of the breast, Mol Cancer Res 1 (2003), 362-375.
142. L. M. Precht et al. , NeoadjuvantChemotherapy of Breast Cancer: Tumor Markers as Predictors of Pathologic Response, Recurrence, and Survival, Breast J.
143. D. M. Radford et al. , Allelic loss and the progression of breast cancer, Cancer Res 55 (1995), 5180-5183.
144. D. C. Radisky and M. A. LaBarge, Epithelial-mesenchymal transition and the stem cell phenotype, Cell Stem Cell 2 (2008), 511-512.
145. E. A. Rakha et al. , Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype, J Clin Oncol 25 (2007), 4772-4778.
146. N. Ramachandran et al. , Tracking humoral responses using self assembling protein microarrays, Proteomics- Clinical Applications 2 (2008), 1518-1527.
147. P. M. Ravdin et al. , Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study, J Clin Oncol 10 (1992), 1284-1291.
148. B. J. Reinhart et al. , The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans, Nature 403 (2000), 901-906.
149. J. S. Reis-Filho et al. , Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity, J Pathol 207 (2005), 1-13.
150. T. Y. Roh et al. , High-resolution genome-wide mapping of histonemodifications, Nat Biotechnol 22 (2004), 1013-1016.
151. J. Rosai, Borderline epithelial lesions of the breast, Am J Surg Pathol 15 (1991), 209-221.
152. E. Rubin et al. , Proliferative disease and atypia in biopsies performed for nonpalpable lesions detected mammographically, Cancer 61 (1988), 2077-2082.
153. D. Sarrio et al. , Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive tometastatic lesions, Oncogene 23 (2004), 3272-3283.
154. U. Scherf et al. , A gene expression database for themolecular pharmacology of cancer, Nat Genet 24 (2000), 236-244.
155. F. C. Schmitt, Multistep progression from an oestrogendependent growth towards an autonomous growth in breast carcinogenesis, Eur J Cancer 31A (1995), 2049-2052.
156. S. J. Schnitt et al. , Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria, Am J Surg Pathol 16 (1992), 1133-1143.
157. M. Shipitsin et al. , Molecular definition of breast tumor heterogeneity, Cancer Cell 11 (2007), 259-273.
158. P. T. Simpson et al. , Molecular evolution of breast cancer, J Pathol 205 (2005), 248-254.
159. F. J. Slack and J. B. Weidhaas,MicroRNAs as a potential magic bullet in cancer, Future Oncol 2 (2006), 73-82.
160. N. Sneige et al. , Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases, Mod Pathol 15 (2002), 1044-1050.
161. J. Soares et al. , Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression, Cancer 85 (1999), 112-118.
162. L. J. Solin, Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast? J Clin Oncol 24 (2006), 1017-1019.
163. T. Sorlie et al. , Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A 100 (2003), 8418-8423.
164. T. Sorlie et al. , Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A 98 (2001), 10869-10874.
165. C. Sotiriou and L. Pusztai, Gene-expression signatures in breast cancer, N Engl J Med 360 (2009), 790-800.
166. C. Sotiriou et al. , Gene expression profiles derived from fine needle aspiration correlate with response to systemicchemotherapy in breast cancer, Breast Cancer Res 4 (2002), R3.
167. C. Sotiriou et al. , Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis, J Natl Cancer Inst 98 (2006), 262-272.
168. J. A. Sparano and S. Paik, Development of the 21-gene assay and its application in clinical practice and clinical trials, J Clin Oncol 26 (2008), 721-728.
169. J. E. Staunton et al. , Chemosensitivity prediction by transcriptional profiling, Proc Natl Acad Sci U S A 98 (2001), 10787-10792.
170. M. S. Tamesa et al. , Detection of autoantibodies against cyclophilinAand triosephosphate isomerase in sera from breast cancer patients by proteomic analysis, Electrophoresis 30 (2009), 2168-2181.
171. R. M. Tamimi et al. , Endogenous sex hormone levels and mammographic density among postmenopausal women, Cancer Epidemiol Biomarkers Prev 14 (2005), 2641-2647.
172. R. M. Tamimi et al. , Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women, J Natl Cancer Inst 99 (2007), 1178-1187.
173. F. A. Tavassoli, Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification, Nat Clin Pract Oncol 2 (2005), 116-117.
174. S. F. Tavazoie et al. , Endogenous human microRNAs that suppress breast cancer metastasis, Nature 451 (2008), 147-152.
175. J. P. Thiery, Epithelial-mesenchymal transitions in development and pathologies, Curr Opin Cell Biol 15 (2003), 740-746.
176. J. P. Thiery et al. , Epithelial-mesenchymal transitions in development and disease, Cell 139 (2009), 871-890.
177. J. E. Tomkiel et al. , Autoimmunity to theM(r) 32,000 subunit of replication protein A in breast cancer, Clin Cancer Res 8 (2002), 752-758.
178. H. Tsuda et al. , Correlation of numerical and structural status of chromosome 16 with histological type and grade of noninvasive and invasive breast carcinomas, Int J Cancer 84 (1999), 381-387.
179. Y. Umekita et al. , Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study, Virchows Arch 424 (1994), 491-494.
180. M. J. van de Vijver et al. , A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med 347 (2002), 1999-2009.
181. M. Volkmann et al. , Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression, Oncology 63 (2002), 297-305.
182. C. B. Vos et al. , E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis, Br J Cancer 76 (1997), 1131-1133.
183. P. L. Wagner et al. , Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases, Am J Clin Pathol 132 (2009), 871-876.
184. F. M. Waldman et al. , Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences, J Natl Cancer Inst 92 (2000), 313-320.
185. C. C. Wang et al. , Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer, Proc Natl Acad Sci U S A 105 (2008), 11661-11666.
186. Y. Wang et al. , Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet 365 (2005), 671-679.
187. M. Weber et al. , Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells, Nat Genet 37 (2005), 853-862.
188. S. R. Wellings andH. M. Jensen, On the origin and progression of ductal carcinoma in the human breast, J Natl Cancer Inst 50 (1973), 1111-1118.
189. S. R. Wellings et al. , An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions, J Natl Cancer Inst 55 (1975), 231-273.
190. M. S. Wicha et al. , Cancer stem cells: an old idea-a paradigm shift, Cancer Res 66 (2006), 1883-1890; discussion 1895-1886.
191. M. Widschwendter and P. A. Jones, DNA methylation and breast carcinogenesis, Oncogene 21 (2002), 5462-5482.
192. B. Wightman et al. , Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans, Cell 75 (1993), 855-862.
193. A. K. Witkiewicz et al. , StromalCD10 and SPARCexpression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence, Cancer Biol Ther 10 391-396.
194. C. N. Wrobel et al. , Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture, J Cell Biol 165 (2004), 263-273.
195. A. Yagihashi et al. , Detection of autoantibodies to surviving and livin in sera from patients with breast cancer, Clin Chim Acta 362 (2005), 125-130.
196. J. Yang and R. A. Weinberg, Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis, Dev Cell 14 (2008), 818-829.
197. L. Zhong et al. , Autoantibodies as potential biomarkers for breast cancer, Breast Cancer Res 10 (2008), R40.
198. S. Zhu et al. , MicroRNA-21 targets tumor suppressor genes in invasion and metastasis, Cell Res 18 (2008), 350-359.
199. D. Zou et al. , Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia, J Pathol 218 (2009), 265-272.